Xeris Biopharma Holdings, Inc. (XERS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Xeris Biopharma reported revenue of $291.8M, up 43.7% from $203.1M the year before. Net income was $554,000 (a 0.2% net margin). Operating margin was 8.5%. Operating activities generated $28.6M of cash. At fiscal year end, Xeris Biopharma held $383.5M in total assets against $369.8M in total liabilities, including $111.0M of cash and equivalents.
Open the full interactive Xeris Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Xeris Biopharma Key Stats
| Share Price | $10.20 |
|---|---|
| Market Cap | $1.76B |
| Revenue YoY Growth | +43.7% |
| 52-Week Range | $5.29 – $10.48 |
| Shares Outstanding | 172.8 million (basic, 2026 Q2) |
Xeris Biopharma Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $49.6M | $110.2M | $163.9M | $203.1M | $291.8M |
| Operating Income | -$115.2M | -$81.9M | -$44.0M | -$33.6M | $24.9M |
| Pre-Tax Income | -$122.7M | -$96.1M | -$63.5M | -$57.1M | $554,000 |
| Income Tax | $0 | -$1.4M | -$1.2M | -$2.3M | $0 |
| Net Income | -$122.7M | -$94.7M | -$62.3M | -$54.8M | $554,000 |
| Diluted EPS | -$1.55 | -$0.70 | -$0.45 | -$0.37 | — |
Xeris Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $74.4M | $85.8M | $83.1M | $92.1M |
| Net Income | $621,000 | $11.1M | $2.2M | -$31.1M |
| Diluted EPS | — | $0.06 | $0.01 | -$0.18 |
Xeris Biopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $67.3M | $122.0M | $67.4M | $71.6M | $111.0M |
| Current Assets | $142.6M | $186.8M | $156.3M | $167.7M | $240.3M |
| Total Assets | $304.4M | $344.5M | $322.6M | $323.1M | $383.5M |
| Current Liabilities | $79.0M | $73.6M | $95.2M | $100.4M | $109.6M |
| Total Long-Term Debt | $88.1M | $187.1M | $190.9M | $232.1M | $220.3M |
| Total Liabilities | $209.1M | $299.3M | $329.4M | $352.7M | $369.8M |
| Shareholders' Equity | $95.2M | $45.2M | -$6.8M | -$29.6M | $13.7M |
Xeris Biopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$95.5M | -$102.9M | -$47.0M | -$37.0M | $28.6M |
| Cash From Investing | $98.0M | $34.5M | -$6.0M | $4.9M | -$696,000 |
| Cash From Financing | $27.2M | $127.5M | -$1.6M | $36.2M | $11.4M |
| Free Cash Flow | -$96.6M | — | — | — | — |
Figures from Xeris Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Xeris Biopharma financials page for every line item.
Xeris Biopharma Company Profile
| Ticker | XERS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Chicago, Illinois |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001867096 |
Frequently Asked Questions
What was Xeris Biopharma's revenue in fiscal 2025?
Xeris Biopharma (XERS) reported revenue of $291.8M for fiscal 2025.
What is Xeris Biopharma's annual revenue history?
Xeris Biopharma's annual revenue by fiscal year: 2021: $49.6M; 2022: $110.2M; 2023: $163.9M; 2024: $203.1M; 2025: $291.8M.
What was Xeris Biopharma's net income in fiscal 2025?
Xeris Biopharma reported net income of $554,000 for fiscal 2025.
What was Xeris Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Xeris Biopharma reported revenue of $92.1M.
How much debt does Xeris Biopharma have?
Xeris Biopharma reported $220.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Xeris Biopharma are outstanding?
Xeris Biopharma reported a weighted average of 172.8 million basic shares outstanding in 2026 Q2.
What is Xeris Biopharma's market cap?
Based on its latest closing price, Xeris Biopharma (XERS) has a market capitalization of about $1.76B.
When does Xeris Biopharma's fiscal year end?
Xeris Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Xeris Biopharma headquartered?
Xeris Biopharma lists its business address in Chicago, Illinois in its SEC filings.